1 Min Read
Dec 14 (Reuters) - Pfizer Inc
* "Will continue to analyze these data to better understand results with goal of further helping these patients"
* Trial did not meet its primary endpoint
* "We are committed to continuing to explore clinical potential of XTANDI across disease continuum"
* Pfizer and Astellas announce top-line results from phase 4 PLATO trial of XTANDI (enzalutamide) capsules in patients with metastatic castration-resistant prostate cancer Source text for Eikon: Further company coverage: